Why you should avoid buying shares in ANZ Bank

'Professional' management and skewed incentives usually result in unhappy returns.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a lacklustre experience being a shareholder in Australia and New Zealand Banking Group (ASX: ANZ) with the share price falling from $27.57 at the beginning of 2008 to $25.73 today.

Inclusive of dividends though, the total annual return for shareholders has been in the vicinity of 7.5% per annum.

In contrast is Australia's best performing bank, Westpac Banking Corp (ASX: WBC) with average annual returns over the same time period of close to 11.5%.

That's quite an underperformance by ANZ, so what's going on?

Last Friday's Australian Financial Review published a critique of ANZ's previous CEO, Mr Mike Smith, who implemented his Asian strategy in an effort to assist Australian and New Zealand businesses with their own expansion strategies in the region and at the same time, perhaps, compete with the big boys of HSBC, Citi and Standard Chartered.

I'm fully supportive of any business wanting to expand, but it has to be done profitably. The argument against ANZ is that its expansion lacked focus and was needlessly costly to its shareholders.

ANZ shareholders have fared badly compared to its competitors, including Commonwealth Bank of Australia (ASX: CBA) and National Australia Bank Ltd. (ASX: NAB):

This is a very disappointing financial outcome for those who have backed Mike Smith's Asian-expansion strategy by owning shares in ANZ.

From late 2007 when Mike Smith was appointed, and as the bank's Asian expansion strategy became more apparent, I wondered then how this would all fare (all from a distance of course as I was never tempted to buy shares in the bank). Would this be a bank to successfully take on the world (or at least SE Asia), or would it return to Australia with its metaphorical tail between its legs?

Well, the answers are now clear and the current CEO, Mr Shayne Elliott, has taken the view that the bank's Asian expansion will be curtailed with more of a focus by the bank now on its digital strategy. The aim is to right the ship and return the bank to higher rates of profitability. I think this turnaround is a damning assessment of Mike Smth's tenure at ANZ.

(As an aside, Mike Smith was paid $88m in compensation for the period he was at ANZ).

Foolish takeaway

Poor financial incentives for CEOs can encourage an empire-building mentality with no thought given to the competitive landscape the company may find itself in as a result of its new strategy, and whether such strategies are ultimately profitable.

I'd avoid investing in ANZ and would rather watch from the sidelines how ANZ's new digital strategy unfolds in the years ahead. The appointment recently of Ms Maile Carnegie (previously Managing Director Australia and New Zealand at Google) is a good start, but the bank is going to have to get some runs on the board.

The bigger takeaway though is this:

Rather than invest in companies with 'professional' management, why not choose smaller companies where the senior management team and Board have a significant financial stake in the business? If Mike Smith owned 15% (or $11.3b) of ANZ, do you think he would have made the same strategic decisions?

Management at founder-led companies such as ARB Corporation Limited (ASX: ARB), National Storage REIT (ASX: NSR) and Freedom Foods Group Ltd (ASX: FNP) have meaningful financial stakes in their respective businesses leading to a shareholder-friendly culture which, I believe, is exactly the opposite of what has happened at ANZ in recent years.

Whilst the full effect of the failed Asian expansion strategy at ANZ could not have been known in advance, you can at least reduce some of your risk by buying into companies where management have aligned themselves with shareholders.

As always, do your own research and know what you're buying.

Motley Fool contributor Edward Vesely owns shares in ARB Corporation. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »